PLIANT THERAPEUTICS, INC. (PLRX) research

PLIANT THERAPEUTICS, INC.
ShareXLinkedInReddit
Sector
Pharmaceuticals
Last price
$1.14
As of

PLIANT THERAPEUTICS, INC. (PLRX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-11.

As of . Source: SEC EDGAR filings for PLRX. Method and limitations.

SHARE THIS CARD

Share the PLRX intelligence card

A branded snapshot of PLRX: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion PLRX intelligence card preview
Post to X
LIVE TERMINAL

See PLRX live in the terminal

Track PLRX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live PLRX terminal, free

Active signals for PLRX

FREE, NO ACCOUNT

Every signal on PLRX, as it fires

You are seeing 5 of 17 signals recorded on PLRX since 2026-06-01.

The five above all landed on 2026-09-06. The other 12 were recorded on 3 other days. 14 of the 17 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in PLRX (2026Q2)

Manager / securityMarket value% portfolioQoQ
TWO SIGMA INVESTMENTS, LPCUSIP 729139105 · 2026Q2$2.6M0.00%,
CITADEL ADVISORS LLCCUSIP 729139105 · 2026Q2$2.4M0.00%,
RENAISSANCE TECHNOLOGIES LLCCUSIP 729139105 · 2026Q2$2.3M0.00%,
MILLENNIUM MANAGEMENT LLCCUSIP 729139105 · 2026Q2$638K0.00%,
Point72 Asset Management, L.P.CUSIP 729139105 · 2026Q2$23K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, PLRX

PLRX against its peers

PLRX's return on equity of -82.4% ranks in the 7th percentile of 21 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.

MetricPLRXPeer medianPercentilen
Revenue FY0.0 USD403M USD519
Gross marginn/a59.3%n/a5
Operating marginn/a10.6%n/a18
Net marginn/a0.6%n/a18
Return on equity-82.4%-9.3%721
P / En/a13.5xn/a9

Peers (24): SIGA, FULC, BIOA, AVIR, COLL, ACRS, ESPR, PCRX, AMPH, ALMS, ANRO, PAHC, INVA, OMER, XERS, ANIP, NUVB, TRVI, BHC, OCUL, NKTR, SUPN, HRMY, GPCR. Left out: ACB (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (PLRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more PLRX signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to PLRXand get the insider, 13F, options, and confluence read in one view.

Open the live PLRX terminal, free